Kabra Drugs Ltd
₹ 12.2
0.00%
16 Jun
2:34 p.m.
About
Incorporated in 1989, Kabra Drugs Limited is engaged in the business of Permaculture manufacturing and trading in pharma related products.
Key Points
- Market Cap ₹ 29.0 Cr.
- Current Price ₹ 12.2
- High / Low ₹ 12.2 / 7.91
- Stock P/E
- Book Value ₹ 10.4
- Dividend Yield 0.00 %
- ROCE -7.82 %
- ROE -8.47 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 1.17 times its book value
Cons
- Company has low interest coverage ratio.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.42 | 8.24 | 9.59 | 7.61 | 1.81 | -0.04 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | |
| 10.84 | 7.77 | 9.14 | 7.17 | 2.84 | 0.09 | 0.05 | 0.15 | 0.18 | 0.35 | 0.74 | 1.72 | |
| Operating Profit | 0.58 | 0.47 | 0.45 | 0.44 | -1.03 | -0.13 | -0.05 | -0.15 | -0.18 | -0.35 | -0.74 | -1.72 |
| OPM % | 5.08% | 5.70% | 4.69% | 5.78% | -56.91% | -150.00% | -3,400.00% | |||||
| -0.03 | 0.01 | 0.02 | 0.11 | -0.94 | 0.01 | 0.02 | -0.00 | -0.00 | 0.01 | -0.00 | 0.64 | |
| Interest | 0.07 | 0.14 | 0.18 | 0.17 | 0.25 | 0.01 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Depreciation | 0.26 | 0.23 | 0.24 | 0.24 | 0.14 | 0.03 | 0.03 | 0.03 | 0.01 | -0.00 | -0.00 | 0.01 |
| Profit before tax | 0.22 | 0.11 | 0.05 | 0.14 | -2.36 | -0.16 | -0.06 | -0.18 | -0.19 | -0.34 | -0.74 | -1.09 |
| Tax % | 59.09% | 36.36% | 40.00% | 7.14% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| 0.09 | 0.07 | 0.03 | 0.13 | -2.36 | -0.16 | -0.06 | -0.18 | -0.19 | -0.34 | -0.74 | -1.09 | |
| EPS in Rs | 0.21 | 0.16 | 0.07 | 0.30 | -5.38 | -0.36 | -0.14 | -0.41 | -0.43 | -0.77 | -1.69 | -0.46 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -47% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -9% |
| 5 Years: | 26% |
| 3 Years: | 38% |
| 1 Year: | 54% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -8% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.39 | 4.39 | 4.39 | 4.39 | 4.39 | 4.39 | 4.39 | 4.39 | 4.39 | 4.39 | 4.39 | 23.71 |
| Reserves | -1.46 | -1.78 | -1.76 | -1.84 | -4.19 | -4.36 | -4.42 | -4.60 | -4.78 | -5.12 | -3.31 | 0.95 |
| 3.01 | 2.81 | 2.39 | 1.80 | 0.70 | 0.67 | 0.65 | 0.90 | 1.03 | 1.38 | 1.71 | 0.44 | |
| 3.27 | 3.12 | 4.15 | 2.03 | 0.80 | 0.78 | 0.79 | 0.71 | 0.09 | 0.05 | 1.78 | 0.13 | |
| Total Liabilities | 9.21 | 8.54 | 9.17 | 6.38 | 1.70 | 1.48 | 1.41 | 1.40 | 0.73 | 0.70 | 4.57 | 25.23 |
| 3.30 | 2.78 | 2.73 | 2.48 | 0.11 | 0.08 | 0.04 | 0.01 | -0.00 | -0.00 | -0.00 | 0.04 | |
| CWIP | -0.00 | 0.10 | 0.21 | 0.21 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| 5.91 | 5.66 | 6.23 | 3.69 | 1.59 | 1.40 | 1.37 | 1.39 | 0.73 | 0.70 | 4.57 | 25.19 | |
| Total Assets | 9.21 | 8.54 | 9.17 | 6.38 | 1.70 | 1.48 | 1.41 | 1.40 | 0.73 | 0.70 | 4.57 | 25.23 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.00 | -0.22 | 0.28 | 0.31 | -0.12 | -0.18 | -0.05 | -0.25 | -0.13 | -0.35 | -0.21 | -4.71 | |
| -0.14 | -0.20 | -0.29 | 0.01 | 1.50 | 0.07 | 0.06 | -0.00 | -0.00 | -0.00 | -0.00 | -0.05 | |
| 0.14 | 0.58 | -0.27 | -0.32 | -1.35 | -0.00 | -0.02 | 0.25 | 0.13 | 0.36 | 2.88 | 23.39 | |
| Net Cash Flow | -0.00 | 0.16 | -0.28 | -0.00 | 0.04 | -0.10 | -0.00 | -0.00 | -0.01 | -0.00 | 2.67 | 18.63 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 146.38 | 198.00 | 204.00 | 141.49 | 254.09 | -11,406.25 | ||||||
| Inventory Days | 31.67 | 25.58 | 16.04 | 16.73 | -0.00 | -0.00 | ||||||
| Days Payable | 79.17 | 129.78 | 139.88 | 97.33 | ||||||||
| Cash Conversion Cycle | 98.88 | 93.81 | 80.16 | 60.89 | 254.09 | -11,406.25 | ||||||
| Working Capital Days | 75.43 | 92.58 | 73.46 | 65.23 | 102.85 | 5,018.75 | ||||||
| ROCE % | 5.52% | 4.40% | 4.41% | 6.62% | -44.19% | -18.75% | -9.09% | -27.48% | -28.57% | -52.71% | -43.02% | -7.82% |
Documents
Announcements
-
Board Meeting Intimation for Intimation Of Proposed Board Meeting Of The Board
9 Jun - Board meeting on June 18 to discuss acquisition, new drug license, and new subsidiary creation.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Jun
-
Appointment Of Secretarial Auditor
30 May - Appointment of Anshu Chouhan & Associates as Secretarial Auditor for FY 2024-25.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Kabra Drugs exempt from Annual Secretarial Compliance Report for FY 2024-25 under SEBI rules.
-
Statement Of Deviation Or Variation Of Funds Under Regulation 32 Of SEBI (LODR) Regulations, 2015
30 May - No deviation in utilization of Rs.21.80 Cr preferential allotment funds as of 31 Mar 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
-
Financial Year 2008
from bse
Product Profile:[1]
a) Cardiovascular Drugs[2]
b) Anti-infective Drugs[3]
c) Oncology Drugs[4]
d) Gastroenterological Drugs[5]
e) Hormonal Drugs[6]
f) Miscellaneous Drugs[7]
g) Active Pharmaceutical Ingredients[8]